Calando, CalTech Researchers Publish Phase I Data on siRNA Cancer Drug
March 25, 2010
Calando, CalTech Researchers Publish Phase I Data on siRNA Cancer Drug
The data, which appeared in the online edition of Nature, "demonstrate that RNAi can occur in a human from a systemically delivered siRNA, and that siRNA can be used as a gene-specific therapeutic," the investigators wrote.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News - Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
August 11, 2011 / Gene Silencing News - Calando Says Strength of Phase I Trial of CALAA-01 Will Attract Partners, Including Suitors
May 20, 2010 / Gene Silencing News - Strands
February 19, 2009 / Gene Silencing News - Arrowhead Offers Timeline for HBV Candidate, Plans Two Phase I Trials
February 14, 2013 / Gene Silencing News